Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| LG Life Science LTD. Snapshot | 7 | 1 |
| LG Life Science LTD. Overview | 7 | 1 |
| Key Facts | 7 | 1 |
| LG Life Science LTD. Research and Development Overview | 8 | 4 |
| Key Therapeutic Areas | 8 | 4 |
| LG Life Science LTD. Pipeline Review | 12 | 7 |
| Pipeline Products by Stage of Development | 12 | 1 |
| Pipeline Products Monotherapy | 13 | 1 |
| Pipeline Products Combination Treatment Modalities | 14 | 1 |
| Pipeline Products Partnered Products | 15 | 1 |
| Partnered Products/Combination Treatment Modalities | 16 | 1 |
| Pipeline Products Out-Licensed Products | 17 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 18 | 1 |
| LG Life Science LTD. Pipeline Products Glance | 19 | 7 |
| LG Life Science LTD. Late Stage Pipeline Products | 19 | 1 |
| Pre-Registration Products/Combination Treatment Modalities | 19 | 1 |
| Phase III Products/Combination Treatment Modalities | 20 | 1 |
| LG Life Science LTD. Clinical Stage Pipeline Products | 21 | 1 |
| Phase II Products/Combination Treatment Modalities | 21 | 1 |
| Phase I Products/Combination Treatment Modalities | 22 | 1 |
| LG Life Science LTD. Early Stage Pipeline Products | 23 | 1 |
| Preclinical Products/Combination Treatment Modalities | 23 | 1 |
| Discovery Products/Combination Treatment Modalities | 24 | 1 |
| LG Life Science LTD. - Unknown Stage Pipeline Products | 25 | 1 |
| Unknown Products/Combination Treatment Modalities | 25 | 1 |
| LG Life Science LTD. Drug Profiles | 26 | 33 |
| (gemigliptin + glimepiride) Drug Profile | 26 | 1 |
| (gemigliptin + metformin hydrochloride) Drug Profile | 27 | 1 |
| (gemigliptin + rosuvastatin calcium) Drug Profile | 28 | 1 |
| (lercanidipine hydrochloride + valsartan) Drug Profile | 29 | 1 |
| adalimumab biosimilar Drug Profile | 30 | 1 |
| etanercept biosimilar Drug Profile | 31 | 1 |
| Eupenta Drug Profile | 32 | 1 |
| exenatide SR Drug Profile | 33 | 1 |
| infliximab biosimilar Drug Profile | 34 | 1 |
| interferon alfa-2a SR Drug Profile | 35 | 1 |
| LBDE Drug Profile | 36 | 1 |
| LBVC Drug Profile | 37 | 1 |
| LBVD Drug Profile | 38 | 1 |
| LBVE-013 Drug Profile | 39 | 1 |
| LBVE-014 Drug Profile | 40 | 1 |
| LC-231306 Drug Profile | 41 | 1 |
| LC-280126 Drug Profile | 42 | 1 |
| LC-280391 Drug Profile | 43 | 1 |
| LC-34AD3 Drug Profile | 44 | 1 |
| LC-350189 Drug Profile | 45 | 1 |
| LC-541239 Drug Profile | 46 | 1 |
| LC-65AOD3 Drug Profile | 47 | 1 |
| LD-02GIFRO Drug Profile | 48 | 1 |
| Monoclonal Antibody to Inhibit VEGF for Cancer Drug Profile | 49 | 1 |
| NecX Drug Profile | 50 | 1 |
| nivocasan Drug Profile | 51 | 1 |
| rituximab biosimilar Drug Profile | 52 | 1 |
| Small Molecule to Inhibit PAR-1 for Atherothrombosis Drug Profile | 53 | 1 |
| Small Molecules for Obesity Drug Profile | 54 | 1 |
| Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor Drug Profile | 55 | 1 |
| somatropin Drug Profile | 56 | 1 |
| somatropin SR Drug Profile | 57 | 2 |
| LG Life Science LTD. Pipeline Analysis | 59 | 8 |
| LG Life Science LTD. Pipeline Products by Target | 59 | 3 |
| LG Life Science LTD. Pipeline Products by Route of Administration | 62 | 1 |
| LG Life Science LTD. Pipeline Products by Molecule Type | 63 | 1 |
| LG Life Science LTD. Pipeline Products by Mechanism of Action | 64 | 3 |
| LG Life Science LTD. Dormant Projects | 67 | 1 |
| LG Life Science LTD. Locations And Subsidiaries | 68 | 2 |
| Head Office | 68 | 1 |
| Other Locations &Subsidiaries | 68 | 2 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |